Boston Partners
CDNA icon

Boston Partners’s CareDx CDNA Stock Holding History

Boston Partners’s Portfolio CDNA Stock Details CDNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$55.2M Buy
1,937,601
+54,067
+3% +$1.18M 0.05% 267
2026
Q1 		$32.7M Buy
1,883,534
+981,605
+109% +$18.6M 0.03% 312
2025
Q4 		$17M Buy
901,929
+870,574
+2,777% +$14.6M 0.02% 383
2025
Q3 		$456K Buy
31,355
+9,864
+46% +$141K ﹤0.01% 689
2025
Q2 		$420K Buy
21,491
+34
+0.2% +$604 ﹤0.01% 673
2025
Q1 		$381K Buy
21,457
+158
+0.7% +$3.4K ﹤0.01% 656
2024
Q4 		$456K Sell
21,299
-353,839
-94% -$8.61M ﹤0.01% 652
2024
Q3 		$11.7M Buy
375,138
+350,849
+1,444% +$8.73M 0.01% 386
2024
Q2 		$377K Buy
+24,289
New +$294K ﹤0.01% 681
2023
Q1 		– Sell
-35,099
Closed -$400K – 704
2022
Q4 		$400K Buy
35,099
+24,905
+244% +$369K ﹤0.01% 623
2022
Q3 		$174K Sell
10,194
-273
-3% -$5.86K ﹤0.01% 680
2022
Q2 		$225K Buy
+10,467
New +$290K ﹤0.01% 667

Other funds holding CDNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return
GA
Gagnon Advisors New York $157M AUM 36.77% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Boston Partners's CDNA Position: Q2 2026 in Review

Boston Partners increased its CareDx (CDNA) stake by 2.9% in Q2 2026, buying an estimated $1.18M and bringing the position to 1,937,601 shares worth $55.2M. The position accounts for 0.05% of the portfolio, ranked #267.

Boston Partners first reported a position in CDNA in Q2 2022 and has held it in 12 quarters since. 91 funds tracked by Wall St. Rank hold CDNA as of Q2 2026.

  • Boston Partners held 1,937,601 shares of CareDx worth $55.2M as of Q2 2026.
  • Boston Partners bought 54,067 CareDx shares in Q2 2026, an estimated $1.18M.
  • CareDx made up 0.05% of Boston Partners's portfolio in Q2 2026, its #267 holding.
  • Boston Partners first reported a position in CareDx in Q2 2022 and has held it in 12 quarters since.
  • 91 funds tracked by Wall St. Rank held CareDx as of Q2 2026.

Based on Boston Partners's 13F filing for Q2 2026, filed 4 Aug 2026.